Efavirenz 600mg + Tenofovir
300mg + Emtricitabine 200mg (Atripla)
[1 NNRTI plus 2 NRTIs]
Zidovudine 300mg + Lamivudine
150mg (Combivir) [2 NRTIs]
Tenofovir 300mg + Emtricitabine
200mg (Truvada) [2 NRTIs]
Abacavir 600mg + Lamivudine
300mg (Epzicom)
[2 NRTIs]
Abacavir 300mg + Zidovudine
300mg + Lamivudine 150mg (Trizivir)
[3
NRTIs] |
 Efavirenz 600mg + Tenofovir
300mg + Emtricitabine 200mg (Atripla)
[1 NNRTI plus 2 NRTIs] |
| • | [P6]
Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz
(EFV) compared to fixed dose Zidovudine/lamivudine (CBV)
and EFV through 96 weeks in antiretroviral treatment-naive patients
A
Pozniak and others. |
| • | [P199]
Study 934: significantly lower frequency of the M184V mutation on FTC + TDF +
EFV compared to combivir + EFV at week 96
D
J McColl and others. |
Zidovudine 300mg + Lamivudine
150mg (Combivir) [2 NRTIs] |
| • | [P392]
Safety and antiviral activity of the novel CCR5 antagonist aplaviroc in combination with zidovudine+lamivudine
in HIV-infected therapy naive subjects
J
Currier and others. |
| • | [P199]
Study 934: significantly lower frequency of the M184V mutation on FTC + TDF +
EFV compared to combivir + EFV at week 96
D
J McColl and others. |
| • | [P6]
Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz
(EFV) compared to fixed dose Zidovudine/lamivudine (CBV)
and EFV through 96 weeks in antiretroviral treatment-naive patients
A
Pozniak and others. |
| • | [P53]
Impact of switching virologically
suppressed, HIV-infected patients from fixed-dose zidovudine/lamivudine
(CBV) to fixed-dose tenofovir DF/emtricitabine
(TVD)
E
DeJesus and others. |
Tenofovir 300mg + Emtricitabine
200mg (Truvada) [2 NRTIs] |
| • | [P61]
Virologic suppression is maintained in antiretroviral
experienced adults who change from tenofovir and lamivudine to Truvada, a once daily
fixed-dose combination tablet of tenofovir and emtricitabine
A E Colson and others. |
| • | [P14]
Cost-effectiveness analysis of tenofovir/emtricitabine
and abacavir/lamivudine in the treatment of antiretroviral
naive HIV-1 infected patients
J Borrill and
others. |
| • | [P1]
Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir
(TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1
infected patients: 24-week results from COL103952 (ALERT)
K
Smith and others. |
| • | [PL2.5]
Saquinavir/r (SQV/r) BID vs
lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir
(FTC/TDF) QD in ARV-naive HIV-1 infected patients: GEMINI Study
J
Slim and others. |
| • | [P6]
Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz
(EFV) compared to fixed dose Zidovudine/lamivudine (CBV)
and EFV through 96 weeks in antiretroviral treatment-naive patients
A
Pozniak and others. |
| • | [P53]
Impact of switching virologically
suppressed, HIV-infected patients from fixed-dose zidovudine/lamivudine
(CBV) to fixed-dose tenofovir DF/emtricitabine
(TVD)
E
DeJesus and others. |
| • | [P152]
The safety and efficacy of tenofovir
DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients
I Cassetti
and others. |
Abacavir 600mg + Lamivudine
300mg (Epzicom)
[2 NRTIs] |
| • | [P170]
Switching from twice daily (BID) abacavir (ABC) and
lamivudine (3TC) to a fixed dose combination (FDC) of ABC/3TC
taken once daily (QD) improves patient adherence and satisfaction with therapy
D Maitland and others. |
| • | [P32]
Simplification to efavirenz + abacavir/lamivudine
(Kivexa) in previously suppressed HIV-infected patients
compared with other conventional regimens of 2 nucleosides + efavirenz: 6-months of follow-up
P Echeverria and others. |
| • | [P7]
Similar antiviral efficacy and tolerability between efavirenz
and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in
naive patients: a multicentre, randomized study
P Echeverria
and others. |
| • | [P14]
Cost-effectiveness analysis of tenofovir/emtricitabine
and abacavir/lamivudine in the treatment of antiretroviral
naive HIV-1 infected patients
J
and others. |
| • | [P2]
Efficacy and safety of once-daily boosted fosamprenavir/ritonavir
(FPV/r) with abacavir (ABC)/lamivudine
(3TC) fixed dose combination in antiretroviral naive HIV-1 infected patients:
24-week results from COL100758
C
Hicks and others. |
| • | [P10]
Once-daily (QD) abacavir (ABC)/lamivudine
(3TC) and ritonavir-boosted atazanavir
(ATV/r) in antiretroviral naïve HIV-1 infected subjects: 24-week analysis from
COL102060 (SHARE)
R Elion
and others. |
| • | [P50]
Study of changes in CD4 cells count after switching tenofovir
to abacavir or TDF and didanosine
to ABC+lamivudine in patients with a ddI+TDF containing regimen and viral suppression (Europa study): preliminary analysis
E
Pedrol and others. |
| • | [P16]
ABC/3TC in combination with a boosted PI in clinical practice
Andreas
Carganico and others. |
Abacavir 300mg + Zidovudine
300mg + Lamivudine 150mg (Trizivir)
[3
NRTIs] |
| • | [PL2.3]
Induction-maintenance antiretroviral therapy with Trizivir
plus either efavirenz or lopinavir/r:
results of a multicentre randomized
clinical trial at 72 weeks
J Mallolas
and others. |
| • | [P226]
Impact of different TAMs on outcome
of a HAART regimen with ABC+3TC+AZT (Trizivir) and TDF
S Dupke
and others. |
| • | [P27]
Response to mono-class nucleoside regimen of tenofovir
DF + trizivir in antiretroviral-experienced patients:
48 week results and predictors of response
B
Dauer and others. |
| • | [P115]
Abacavir
hypersensitivity reaction in EuroSIDA
W Bannister and others. |
11/28/06 Source
Abstracts of the 8th International Congress on Drug Therapy in
HIV Infection (HIV8). http://www.abstracts2view.com/hiv
November 12-16, 2006. Glasgow,
UK. |
|
